References
- Clark H. NCDs: a challenge to sustainable human development. Lancet Lond Engl. 2013;381:510–511.
- Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1–25.
- World Health Organization. Cardiovascular diseases (CVDs) [ Internet]. [cited 2019 Aug 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- Owolabi M, Miranda JJ, Yaria J, et al. Controlling cardiovascular diseases in low and middle income countries by placing proof in pragmatism. BMJ Glob Health. 2016;1:e000105.
- Prabhakaran D, Jeemon P, Sharma M, et al. The changing patterns of cardiovascular diseases and their risk factors in the states of India: the global burden of disease study 1990–2016. Lancet Glob Health. 2018;6:e1339–e1351.
- American Heart Association. Cardiovascular disease: a costly burden for America. Projections through 2035 [Internet]. 2017. Available from: https://healthmetrics.heart.org/wp-content/uploads/2017/10/Cardiovascular-Disease-A-Costly-Burden.pdf
- Gheorghe A, Griffiths U, Murphy A, et al. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health. 2018;18:975.
- Huffman MD, Rao KD, Pichon-Riviere A, et al. A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS ONE [Internet]. 2011 [cited 2020 June 1];6(6):e20821. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114849/
- Bloom DE, Cafiero-Fonseca ET, Candeias V, et al. Economics of non-communicable diseases in india: the costs and returns on investment of interventions to promote healthy living and prevent, treat, and manage NCDs. World Economic Forum, Harvard School of Public Health, Geneva, Switzerland; 2014. p. 2014.
- National Health Systems Resource Centre. National Health Accounts Estimates for India (2015-16), New Delhi, Ministry of Health and Family Welfare, Government of India. 2018.
- WHO. Guideline on country pharmaceutical pricing policies [ Internet]. 2015. Available from: https://apps.who.int/iris/bitstream/handle/10665/153920/9789241549035_eng.pdf;jsessionid=989B22BCD4673A661E807323004BBB1A?sequence=1.
- Selvaraj S, Farooqui HH, Karan A. Quantifying the financial burden of households’ out-of-pocket payments on medicines in India: a repeated cross-sectional analysis of national sample survey data, 1994–2014. BMJ Open. 2018;8:e018020.
- Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet Lond Engl. 2009;373:240–249.
- Prinja S, Bahuguna P, Tripathy JP, et al. Availability of medicines in public sector health facilities of two North Indian states. BMC Pharmacol Toxicol. 2015;16:1–11.
- Pandey KR, Meltzer DO. Financial burden and impoverishment due to cardiovascular medications in low and middle income countries: an illustration from India. Plos One. 2016;11:e0155293.
- Department of Pharmaceuticals. Drug price control order [ Internet]. 2013. Available from: http://pharmaceuticals.gov.in/pdf/dpco2013gaz.pdf
- National Pharmaceutical Pricing Authority , Ministry of Chemicals & Fertilizers, Government of India [Internet]. [ Internet]. [cited 2020 May 30]. Available from: http://www.nppaindia.nic.in/en/14/8090/23/18/01/26/2019/
- Ministry of Health and Family Welfare, GOI. National list of essential medicines of India - 2015 [ Internet]. Available from: https://mohfw.gov.in/sites/default/files/NLEM%2C%202015.pdf
- Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13e New York: McGraw-Hill Medical, 2018.
- CIMS prescriber’s handbook. Bengaluru: CIMS Medica India Pvt. Ltd; 2018 ;40(3).
- Drug Today. Delhi: Lorina Publications India Inc. 2018; 26(2).
- Current Index of Medical Specialties [Internet]. [cited 2019 Nov 27]. Available from: https://www.mims.com/india/latestupdate/list.
- WHO. 3. Defined daily dose (DDD) [ Internet]. WHO; [cited 2019 Aug 22]. Available from: http://www.who.int/medicines/regulation/medicines-safety/toolkit_ddd/en/
- WHO Collaborating Centre for Drug Statistics Methodology. Purpose of ATC/DDD system [ Internet]. Available from: https://www.whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system/
- WHO Collaborating Centre for Drug Statistics Methodology. WHOCC - ATC/DDD index [ Internet]. [cited 2019 Aug 22]. Available from: https://www.whocc.no/atc_ddd_index/
- Kuper KM. Text book of competence assessment tools for health-system pharmacies, 4th ed. ASHP; 2008. p. 347–360. Intravenous to oral therapy conversion. Bethesda, MD.
- Cyriac JM, James E. Switch over from intravenous to oral therapy: a concise overview. J Pharmacol Pharmacother. 2014;5:83–87.
- Central Drugs Standard Control Organization. [ Internet]. [cited 2019 Nov 27]. Available from: https://cdscoonline.gov.in/CDSCO/Drugs
- Hauptman PJ, Goff ZD, Vidic A, et al. Variability in retail pricing of generic drugs for heart failure. JAMA Intern Med. 2017;177:126–128.
- Kullgren JT, Segel JE, Peterson TA, et al. Availability and variation of publicly reported prescription drug prices. Am J Manag Care. 2017;23(7):444-448.
- Mishra SR, Kandel N, Subedi N, et al. Variation in prices of cardiovascular drugs in public and private pharmacies in Nepal. Health Serv Res Manag Epidemiol [Internet]. 2015 [cited 2019 Nov 22];2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266450/
- Bangalee V, Suleman F. Has the increase in the availability of generic drugs lowered the price of cardiovascular drugs in South Africa? Health SA Gesondheid Online. 2016;21:60–66.
- WHO. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries [ Internet]. WHO [cited 2019 Nov 22]. Available from: https://www.who.int/bulletin/volumes/85/4/06-033647/en/
- Chawan VS, Gawand KV, Badwane SV. Cost analysis of oral hypolipidemic agents available in India. Int J Basic Clin Pharmacol. 2017;3:954–957.
- van Mourik MS, Cameron A, Ewen M, et al. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010;10:25.
- Reif MC, Carter VL. The retail cost of antihypertensive therapy: physician and patient as educated consumers. Am J Hypertens. 1994;7:571–575.
- King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J. 2002;43:462–469.
- Wiggins SN, Maness R. Price competition in pharmaceuticals: the case of anti-infectives. Econ Inq. 2004;42:247–263.
- Bresnahan TF, Reiss PC. Entry and competition in concentrated markets. J Political Econ. 1991;99:977–1009.
- Van Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res. 2012;1:527–538.
- Fatokun O. Chapter 13 - assessment of policies, determinants, and characteristics of generic medicines entry into the pharmaceutical markets. In: Ibrahim MIM, Wertheimer AI, Babar Z-U-D, editors. Social and administrative asp pharmacy low- middle-income countries [ Internet]. Academic Press; 2018 [cited 2019 Nov 26]. p. 211–225. Available from: http://www.sciencedirect.com/science/article/pii/B9780128112281000133
- Danzon PM, Furukawa MF Cross-national evidence on generic pharmaceuticals: pharmacy vs. physician-driven markets [Internet]. National Bureau of Economic Research; 2011 [cited 2019 Nov 26]. (Report No.: 17226). Available from: http://www.nber.org/papers/w17226
- Fatokun O, Ibrahim MI, Hassali MA. Generic competition and drug prices in the Malaysian offpatent pharmaceutical market. J Appl Pharm Sci. 2011;1:33–37.
- Karve AV, Chattar KB. Cost analysis study of oral antihypertensive agents available in Indian market. Int J Basic Clin Pharmacol. 2017;3:479–483.
- Simoens S. International comparison of generic medicine prices. Curr Med Res Opin. 2007 Nov 1;23(11):2647–2654.
- Vogler S, Kilpatrick K, Babar Z-U-D. Analysis of medicine prices in New Zealand and 16 European countries. Value Health. 2015;18:484–492.
- Wagner JL, McCarthy E. International differences in drug prices. Annu Rev Public Health. 2004;25:475–495.
- Wouters OJ, Kanavos PG. A comparison of generic drug prices in seven European countries: a methodological analysis. BMC Health Serv Res. 2017;17:242.
- Henry D. Pharmaceutical Pricing Policy. In: managing access to medicines and health technologies. Arlington, VA: Management Sciences for Health; 2012.
- Dean EB. Who benefits from pharmaceutical price controls? Evidence from India - working paper 509. Cent Global Dev [ Internet]. [cited 2019 Nov 26]. Available from: https://www.cgdev.org/publication/who-benefits-pharmaceutical-price-controls-evidence-india
- Kakkar AK, Shafiq N, Malhotra S. Ensuring access to ‘access’ antibiotics: an imminent consideration for sustainable antimicrobial stewardship in the developing world. Infect Dis. 2019;51:395–398.
- Sahay A, Jaikumar S. Does pharmaceutical price regulation result in greater access to essential medicines? Study of the impact of drug price control order on sales volume of drugs in India [ Internet]. Indian Institute of Management Ahmedabad, Research and Publication Department; 2016 Feb 9.
- van der Gronde T, Groot CAU, Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: a systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. Plos One. 2017;12:e0182613.
- Kwon H-Y, Kim H, Godman B, et al. The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs. Expert Rev Pharmacoecon Outcomes Res. 2015;15:1007–1014.
- Alpern JD, Stauffer WM, Kesselheim AS. High-cost generic drugs — implications for patients and policymakers. N Engl J Med. 2014;371:1859–1862.
- PhD AS JD. Why many generic drugs are becoming so expensive [Internet]. Harv Health Blog. 2015 [cited 2020 June 2]. Available from: https://www.health.harvard.edu/blog/why-many-generic-drugs-are-becoming-so-expensive-201510228480
- WHO Collaborating Centre for Drug Statistics Methodology WHOCC - use of ATC/DDD [ Internet]. [cited 2020 June 2]. Available from: https://www.whocc.no/use_of_atc_ddd/